ZYMAR Drug Patent Profile

When do Zymar patents expire, and what generic alternatives are available?

Zymar is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in ZYMAR is gatifloxacin. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zymar

A generic version of ZYMAR was approved as gatifloxacin by SANDOZ on July 11^th, 2016.

Summary for ZYMAR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Patent Applications:	4,929
DailyMed Link:	ZYMAR at DailyMed

Paragraph IV (Patent) Challenges for ZYMAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYMAR	Ophthalmic Solution	gatifloxacin	0.3 %	021493	1	2007-07-19

US Patents and Regulatory Information for ZYMAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ZYMAR	gatifloxacin	SOLUTION/DROPS;OPHTHALMIC	021493-001	Mar 28, 2003		DISCN	Yes	No

International Patents for ZYMAR

See the table below for patents covering ZYMAR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	610491
Australia	6769087
Canada	1340316	ACIDE 8-ALCOXYQUINOLONECARBOXYLIQUE ET SES SELS, EXCELLENTS POUR LA TOXICITE SELECTIVE; METHODE DE PREPARATION (8-ALKOXYQUINOLONECARBOXYLIC ACID SALTS THEREOF EXCELLENT IN THE SELECTI VE TOXICITY AND PROCESS OF PREPARING THE SAME)
China	1021052
China	87100580

Supplementary Protection Certificates for ZYMAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0230295	300110	Netherlands
0230295	C300110	Netherlands		PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022

Last updated: June 4, 2026

ZYMAR (gatifloxacin ophthalmic solution): market dynamics and financial trajectory (U.S.)

What is ZYMAR’s market position in ophthalmology and how has demand evolved?

ZYMAR is a brand of gatifloxacin ophthalmic solution (topical fluoroquinolone) used for ophthalmic bacterial infections. Market dynamics for this class are shaped by (1) chronic generics pressure, (2) limited new clinical differentiation, (3) payer-driven substitution to low-cost authorized generics and multi-source brands, and (4) cyclical demand tied to ocular infection incidence and provider prescribing patterns.

Class-level demand forces (fluoroquinolone drops for bacterial keratitis and conjunctivitis):

• Price erosion has been the dominant factor as multiple ANDA products entered across the U.S. market for fluoroquinolone ophthalmics.
• Channel mix typically shifts toward contracted wholesalers, group purchasing organizations, and mail-order formularies after generic entries.
• Clinical inertia persists where clinicians prefer a known fluoroquinolone, but this yields to formulary-driven switching when prices compress.

Implications for ZYMAR’s trajectory:

• As a legacy brand in an aging fluoroquinolone space, ZYMAR’s financial path is expected to follow a typical pattern: peak brand uptake, steady share erosion with generic competition, and then a flattened or declining revenue line after major generic/authorized-generic penetration.

How many ZYMAR products compete in the U.S., and what does the competitive landscape look like?

The U.S. ophthalmic fluoroquinolone market is crowded, with multiple multi-source products across agents used for bacterial ocular infections. Competitive products can include other fluoroquinolones (eg, besifloxacin, ciprofloxacin, levofloxacin, moxifloxacin) and generic gatifloxacin formulations where available.

Competitive landscape that impacts ZYMAR:

• Direct substitution at the same therapeutic use and similar administration regimens.
• Retail acquisition cost advantage for generics and authorized generics.
• Fresher formulary preferences for agents with established payer contracting and patient-co-pay profiles, even when therapeutic equivalence exists.

What is the financial trajectory of ZYMAR since launch, and what revenue risks follow patent and exclusivity loss?

ZYMAR’s revenue dynamics track exclusivity. Once generic entry occurs (through ANDA approvals with carve-outs or after patent and data exclusivity windows expire), brand revenues typically compress quickly due to:

• Wholesale price drops and
• Retail substitution.

Key financial risk channels for a legacy ophthalmic brand:

1. ANDA launch timing risk: even small delays affect quarterly revenue recognition in ophthalmics where prescribing volumes shift fast.
2. Authorized generic risk: if a sponsor introduces an authorized generic during or after litigation, price competition can begin earlier than expected.
3. NDC-level erosion: revenue can decline even if some SKUs remain branded, due to SKU switching to lower-cost presentations.

Expected trajectory pattern for ZYMAR:

• Early growth until market penetration stabilizes.
• Then gradual decline as multi-source products expand.
• Acceleration after the most important exclusivity and patent barriers clear.

What role do payer formularies and pharmacy benefit managers play in ZYMAR sales?

For topical ophthalmics, formularies heavily influence script capture through:

• Step edits or preferred product lists for fluoroquinolones,
• Automatic substitution where permitted,
• Contracting that favors lowest-net-cost SKUs.

Net price compression mechanics:

• Brands often maintain market presence by offering rebates that preserve formulary placement.
• When margin becomes uncompetitive, brands lose preferred status, leading to volume loss.

How does ZYMAR’s pricing and discounting typically change under generic competition?

Under generic competition, ophthalmic brands tend to:

• Reduce list price while maintaining rebate intensity, or
• Exit preferred tiers when contracting economics no longer justify rebates.

What this means for financial trajectory:

• Declining revenues can occur even without absolute market shrinkage, because brand unit economics deteriorate and share falls.
• Net revenue declines can outpace unit declines when wholesale rebates and payer concessions increase to preserve placement.

What regulatory pathway status applies to ZYMAR, and how does it affect market entry timing?

ZYMAR is an FDA-approved prescription ophthalmic product (gatifloxacin). The regulatory pathway for competitors is typically via ANDA (generics) if formulation/labeling are supported and exclusivity barriers are cleared.

How regulatory status affects market dynamics:

• Any remaining exclusivity tied to the reference product slows generic approvals and marketing.
• If exclusivity or patents remain, ANDA applicants may proceed with Paragraph IV certifications but can face litigation stays, affecting launch dates.

What patents protect ZYMAR commercially, and when does exclusivity end?

No patent-expiration, Orange Book listing, or exclusivity-date specifics are provided in the input. Without those, an accurate, litigation-ready timeline for ZYMAR’s exclusivity and patent estate cannot be constructed.

Which ZYMAR patent litigations matter for market timing and generic launch outcomes?

No litigation docket details or case identifiers are provided in the input. Without that, a defensible account of Paragraph IV outcomes, settlements, or court rulings cannot be produced.

What generic entry risks exist for ZYMAR, including Paragraph IV pathways?

No Orange Book entry, ANDA history, or Paragraph IV certification timeline is provided in the input. Without these, generic-entry risk cannot be quantified.

How does ZYMAR compare with other ophthalmic fluoroquinolones in market performance drivers?

When comparing ophthalmic fluoroquinolones, the market differentiators that most affect financial outcomes are:

• Net price and formulary position (payer contracting),
• SKU availability (bottle size and dosing convenience),
• Reputation and prescribing habits among cornea and retina specialists,
• Generic substitution velocity based on approved product breadth.

In general, the agent that wins contracting terms and has broader multi-source availability captures share quickly after exclusivity erosion.

Where is ZYMAR most exposed financially: which geographies and channels matter most?

U.S. exposure is typically dominant for legacy ophthalmic brands. Channel economics are driven by:

• Large wholesaler distribution,
• National account formularies,
• Retail pharmacy substitution behavior,
• Specialty pharmacy dynamics are usually less relevant than for biologics, but still matter for paid volumes depending on reimbursement structure.

Without explicit segment reporting, revenue exposure can only be described in structural terms: the key risk is U.S. formulary loss leading to rapid unit share erosion.

What commercial levers can extend ZYMAR revenue before full erosion?

In multi-source ophthalmics, revenue-preservation levers include:

• Maintaining preferred formulary status via rebates,
• Retaining niche prescriber loyalty through clinical familiarity,
• Defending specific NDCs through limited SKU switching where allowed,
• Monitoring ANDA launches and adjusting contracting and trade terms.

These levers often delay but rarely prevent the decline once generics gain broad NDC availability.

Key Takeaways

• ZYMAR’s market dynamics are dominated by generic substitution, payer contracting, and wholesale/net price erosion typical of legacy ophthalmic fluoroquinolone brands.
• The financial trajectory follows a brand-to-multi-source transition, where revenue declines are driven more by net pricing and formulary loss than by underlying incidence trends.
• A quantified exclusivity, patent, and litigation timeline for ZYMAR cannot be produced from the provided input.

FAQs

1. How do rebates and payer formulary tiers change after ZYMAR generic entry?
2. What is the typical time lag between ANDA approval and real-world pharmacy substitution for ophthalmic antibiotics?
3. Do ophthalmic fluoroquinolone switches depend more on prescriber preference or on PBM step edits?
4. How do authorized generics affect revenue pacing for legacy ophthalmic brands like ZYMAR?
5. What NDC-level factors most influence ZYMAR unit erosion after multi-source launches?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. FDA database).
2. FDA. ANDA regulatory framework and data exclusivity principles. (U.S. FDA guidance and resources).